



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Acelarin

Cat. No.:	HY-100885		
CAS No.:	840506-29-8		
Molecular Formula:	$C_{25}H_{27}F_2N_4O_8P$		
Molecular Weight:	580.47		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



## SOLVENT & SOLUBILITY

### In Vitro

DMSO :  $\geq 36$  mg/mL (62.02 mM)  
 \* " $\geq$ " means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.7227 mL	8.6137 mL	17.2274 mL
	5 mM		0.3445 mL	1.7227 mL	3.4455 mL
	10 mM		0.1723 mL	0.8614 mL	1.7227 mL

Please refer to the solubility information to select the appropriate solvent.

### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility:  $\geq 2.08$  mg/mL (3.58 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline)  
 Solubility:  $\geq 2.08$  mg/mL (3.58 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility:  $\geq 2.08$  mg/mL (3.58 mM); Clear solution

## BIOLOGICAL ACTIVITY

### Description

Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.

### IC<sub>50</sub> & Target

EC<sub>50</sub> 0.2 nM (DNA synthesis inhibitor)<sup>[1]</sup>

### In Vitro

Gemcitabine is a nucleoside analogue commonly used in cancer therapy but with limited efficacy due to a high susceptibility to cancer cell resistance. The addition of a phosphoramidate motif to the gemcitabine can protect it against many of the key cancer resistance mechanisms. A series of gemcitabine phosphoramidate prodrugs are synthesized and screened for cytostatic activity in a range of different tumor cell lines. Among the synthesized compounds, NUC-1031 is shown to be

potent in vitro.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

The ProTide demonstrates a significant reduction in tumor size against pancreatic xenograft models compared with the gemcitabine treated group, and less adverse effects on body weight, indicating a better safety profile. Data strongly suggests that the ProTides are not reliant on kinases or nucleoside transporters to exert their activity inside tumor cells and remain stable in the presence of deaminases. The ProTide NUC-1031 is currently advancing through phase I/II clinical studies and has already generated strong pharmacokinetic data that confirm significantly higher intracellular levels of gemcitabine triphosphate, together with promising early efficacy signals and a favorable safety profile. The phosphoramidate chemistry is potentially a great source of new and very effective anticancer agents, bringing a considerable array of advanced treatments specifically designed to overcome cancer resistance mechanisms that will benefit a greater proportion of patients<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Cell Assay<sup>[1]</sup>

NUC-1031(5.0 mg) is dissolved in DMSO (0.050 mL) and D<sub>2</sub>O (0.15 mL). After recording the control <sup>31</sup>P NMR at 37 °C, a previously defrosted human, rat, or dog serum (0.30 mL) is added to the sample, which is next submitted to the <sup>31</sup>P NMR experiments at 37°C. The spectra are recorded every 30 min over 13 h. <sup>31</sup>P NMR recorded data are processed and analyzed with the Bruker Topspin 2.1 program<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration<sup>[1]</sup>

Balb/c nude mice are female, six to eight week old, with the weight of 20 ± 2 g. They are intraperitoneally given NUC-1031 (i.p 0.228 mmol/kg, 132.3 mg/kg, 2×/WK) or vehicle for 2 weeks. NUC-1031 is dissolved in 40% Captisol solution. (40% Captisol is prepared by dissolving 20mg of Captisol with pure water, and made the final volume 50 mL. The solvent is filtered with 0.22 µm filter). Mice are monitored daily for body weight change and clinical symptoms for 2 weeks<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Cancer Chemother Pharmacol. 2020 Jun;85(6):1063-1078.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA